Technical Manual

Terms and conditions

Things you need to know

1.   The following are part of the contract between the exhibitor and/or sponsor and the congress managers, MCI Australia, and exhibitors/sponsors must observe these rules. In addition, any regulations imposed by the virtual platform must also be observed. Any areas not covered are subject to MCI’s final decision.

  • 1.1.   You (the sponsor/exhibitor) by returning a completed, signed and dated form explicitly accept these terms and conditions.
  • 1.2.   Details may change without notice. Please refer to the congress website for the latest information.
  • 1.3.   MCI Australia (ABN 76 108 781 988) representing the organising committee and the Host body does not accept responsibility for any errors, omissions or changes.
  • 1.4.   You agree that the organisers and other authorised stakeholders may use your contact information for any relevant purpose such as administration or advising of future events. You may ask us to limit communication to necessary matters.
  • 1.5.   The Platform and MCI do not take responsibility should internet connection become unstable. Internet connection is out of the control of MCI Australia and the Platform provider, it is the responsibility of the delegate/sponsor/stakeholder to have stable connection to access the platform.
  • 1.6.   We will use reasonable endeavours to provide constant, uninterrupted access to the Platform and the Services, but with any software product, this cannot be guaranteed. We will not be responsible or liable for any direct or indirect losses or damages suffered or sustained by you as a result of, or in connection with, any interruption or delay in accessing and using the Platform or the Services
Use of the platform

2.   You will not, and you will ensure the Authorised Users will not:

  • 2.1.   Modify the platform or merge any aspects of the platform with another programme other than as expressly provided under this Agreement.
  • 2.2.   Record, reverse engineer, copy, duplicate, reproduce, create derivate works from, frame, download, display, transmit or distribute any of the Platform, the source code of the Platform or any documents, manuals or setup instructions provided with the Platform or in relation to the Services
  • 2.3.   License, sell, rent, lease, transfer, assign or otherwise commercially exploit the Platform or the Services
  • 2.4.   Engage in unlawful behaviour, including unauthorised access to or use of data, services, systems or networks, including an attempt to probe, scan or test the vulnerability of a system or network or to break security or authentication measures
  • 2.5.   Access, store, distribute or transmit:
    • 2.5.1.   Viruses, work, trojan or other malicious code that corrupts, degrades or disrupts the operation of the Platform;
    • 2.5.2.   Material that is unlawful, unethical, harmful, threatening, defamatory, obscene, infringing, harassing or racially or ethnically offensive or a contravention of the rights of any third party;
    • 2.5.3.   Material that facilitates illegal activity, or
    • 2.5.4.   Material that abuses or causes damage or injury to any person or property
  • 2.6.   Provide Platform login details or password, or otherwise provide access to the Platform, to any unauthorised or unregistered third party and you will take all reasonable steps to prevent unauthorised access to, or use of, the Platform;
  • 2.7.   Share any features of the Platform that are not publicly available with any unauthorised third part; and
  • 2.8.   Engage in any conduct on the Platform that is in breach of this Agreement (or any agreements mentioned therein)
  • 2.9.   Any breach of this clause 1 constitutes a breach of this Agreement and we may, at our absolutely discretion, terminate or suspend your access to, and/or use of, the Platform or the Services, and/or take further actions against you for breach of this Agreement.
Services

3.   Services

  • 3.1.   All Services will be provided based on the information and specifications supplied by you. All information that we provide is supplied in good faith, but we do not warrant or guarantee the accuracy or completeness of any information provided by us or any third party. It is not within the scope of our obligations to enquire as to, or to verify, the accuracy of completeness of information that we receive from your or any third parties.
  • 3.2.   The Services, Deliverables and any Platform functionality specified in previous conversations are indicative only and may be amended by us from time to time. While we will use all reasonable endeavours to deliver the features and functionality specified therein, nothing in this Agreement prevents us from amending the Services at any time during the event delivery.
  • 3.3.   We will use reasonable endeavours to provide the Services promptly or by an applicable Delivery Date or such other dates as agreed by the parties in writing. Any Delivery Date or time quoted for delivery, commencement or completion of any part of the Services is an estimate only and time will not be of the essence.
Your obligations

4.   Your obligations

  • 4.1.   You acknowledge that our ability to be able to provide the Platform and the Services to you without delate or interruption is dependent on your full and timely cooperation. You will (and will ensure that the Authorised Users will)
    • 4.1.1.   Co-operate with and assist us in the supply of your Platform content;
    • 4.1.2.   Promptly provide us with full and accurate information, data and explanations as and when required;
    • 4.1.3.   Comply with applicable laws and regulations (including the General Data Protection regulation (“GDPR”) with respect to user privacy, data collection, data retention, data transmission, data storage and the use of cookies
    • 4.1.4.   Comply with all reasonable directions and guidelines from us as advised from time to time.
Financial facts

5.   We will have no liability for any losses suffered or any damage caused by errors or omissions in any information or instructions provided to us by you in connection with the Platform, the Services or any actions taken by as at your direction.

  • 5.1.   In no event will MCI Australia/APLAR be liable to you or any third party for any:
    • 5.1.1.   Loss of profits, revenue, goodwill or business, business interruption, corruption, loss or alteration of data, downtime costs, loss of use, failure to realise anticipated savings or for any indirect or consequential loss of damage of whatsoever nature, however caused;
    • 5.1.2.   Viruses worm, trojan or other malicious code introduced into, or transmitted to, your or any third part during the course of using the Platform or the Services;
You and your staff

6.   Your application to sponsor or exhibit does not constitute an attendee registration. You will need to do that separately as per the information provided in the manual.

  • 6.1.   Your staff (even if entitled to a complimentary registration) will be denied access to the event or exhibition unless they have completed the relevant registration form.
Exhibitor notes

7.   Exhibitor notes

  • 7.1.   You have a limited licence to exhibit. You may not assign, share, sub-let, or grant registrations for the whole or part of the booth without our prior approval.
  • 7.2.   We are the sole judge of acceptable display items and you will remove them promptly if asked.
  • You will be responsible for any reasonable costs should contents of your exhibition need to be changed, removed or updated.
  • 7.3.   You and your staff must be attired and behaved in accordance with the professional atmosphere of the event.
Iridex

Iridex

At Iridex, we are redefining the glaucoma treatment paradigm with a versatile range of non-incisional, laser-based therapies: MicroPulse Laser Trabeculoplasty, MicroPulse Transscleral Laser Therapy, and Continuous-Wave Transscleral Cyclophotocoagulation. These therapies
provide physicians safe, effective, and versatile treatment options for a wide variety of glaucoma types and severities, to significantly reduce intraocular pressure and slow the progression of vision loss. More than 200,000 patients have been treated since 2015 with MicroPulse® TLT using the MicroPulse P3® Delivery Device. Visit iridex.com/webinars to learn how ophthalmologists and patients benefit from our non-incisional glaucoma procedures.

Kalson

Kalson Surgical

Bayer

Bayer Co. (Malaysia) Sdn Bhd

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.

DKSH_500x500

DKSH

DKSH is the leading growth partner for pharmaceutical companies in Asia. Our experts provide a range of integrated Market Expansion Services across the entire value chain, ranging from registration through to marketing, promotion and distribution.
Our capillary network reaches more than 130,000 hospitals, clinics, pharmacies, doctors and drugstores in Asia. Products are transported, stored and distributed efficiently thanks to our unmatched capacities and expertise in the region. Our solid infrastructure and dedication to compliance and quality reduce business risks for our partners.
We are committed to delivering the results you need to be successful. That’s why we continuously invest in our sales and marketing organization, which is fully embedded in our operations. Our teams work with clear measurements, activity-driven KPIs and standardized brand planning processes across the region. They are supported by regional Sales and Marketing Excellence and Business Development teams, allowing us to duplicate success across markets.
Headquartered and publicly listed in Switzerland, our local experts provide services to pharmaceutical companies in 13 Asian markets.

Glaukos Aventisin 500x500

Glaukos Corporation / Aventisin

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.

In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for
glaucoma, corneal health, and retinal diseases.

Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in 9 regions around the world.

TRB

TRB Chemedica Malaysia

A subsidiary company of TRB CHEMEDICA INTERNATIONAL SA (Switzerland) established for almost 34 years in Malaysia, specialising in the use of hyaluronic acid in ophthalmology, rheumatology and orthopaedic for the management of ocular dryness, osteoarthritis and tendinopathy.

Nova Eye

Nova Eye Medical

With a legacy that spans more than 30 years in ophthalmology, Nova Eye Medical designs, develops, manufactures and markets a portfolio of proprietary glaucoma treatment technologies. Underpinning each of these technologies is our commitment to advance clinical outcomes and improve patient quality of life.

icare

Icare

iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD).
Our devices cover automated fundus imaging systems, perimeters, and handheld rebound tonometers. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
We believe that ophthalmic care must be accessible, effortless, and reliable, and our aim is to establish the next level of eye care.

Alcon

Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Santen

Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit https://www.santen.asia/

placeholder.png

Speaker Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

placeholder.png

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Contact